FilingReader Intelligence
Huahai Pharmaceutical gets clinical trial approval for new drug
July 31, 2025 at 09:39 AM UTC•By FilingReader AI
Zhejiang Huahai Pharmaceutical received approval from China's National Medical Products Administration for clinical trials of HB0043 injection, a treatment for hidradenitis suppurativa.
The company invested approximately RMB 69.09 million in developing the recombinant humanized antibody targeting IL-17A and IL-36R.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime